CAS · 496775-62-3
Product Overview
Eltrombopag Olamine is a high-purity a-api supplied for industrial and specialty chemical applications. Contact our team for specifications, packaging options and lead times.
Product Specifications
| Appearance | Red to brown solid |
|---|---|
| Purity by HPLC | 99% min |
| Residual Solvents | Methanol: 0.3% max Ethanol: 0.5% max Triethylamine: 0.006% max |
| Residue on ignition | 0.2% max |
| LOD | 0.5 max |
Applications
1. Treatment of Thrombocytopenia
Primarily used to increase platelet counts in patients with conditions characterized by low platelet levels:
Chronic immune thrombocytopenia (ITP)
Thrombocytopenia secondary to hepatitis C virus (HCV) infection
Severe aplastic anemia
Acts by stimulating the thrombopoietin receptor (c-Mpl receptor) on megakaryocyte precursors, promoting platelet production in the bone marrow.
2. Support in Hematology and Oncology
Used in patients undergoing chemotherapy or bone marrow suppression to reduce bleeding risk due to low platelets.
Helps minimize need for platelet transfusions, reducing transfusion-related complications.
3. Orphan Drug for Rare Disorders
Approved for use in rare hematological conditions involving impaired platelet production.
Provides an important alternative to immunosuppressants or corticosteroids in resistant thrombocytopenia cases.
Benefits
1. Oral Administration and Patient Compliance
Administered orally, offering an easier alternative to injectable therapies like recombinant thrombopoietin.
The olamine salt form enhances solubility and bioavailability, enabling consistent and effective dosing.
2. Targeted Mechanism of Action
Eltrombopag Olamine丨CAS 496775-62-3 specifically activates the c-Mpl receptor, promoting megakaryocyte proliferation and differentiation, which directly boosts platelet production.
Helps restore normal platelet counts without widespread bone marrow stimulation.
3. Reduction in Bleeding Complications
By increasing platelet counts, eltrombopag reduces bleeding episodes, improving quality of life and clinical outcomes for patients with thrombocytopenia.
May allow patients to continue chemotherapy or antiviral therapy by managing platelet-related side effects.
4. Long-Term Safety Profile
Generally well tolerated with a manageable side effect profile when monitored.
Allows for chronic administration in diseases like ITP, supporting long-term management.
Conclusion
Eltrombopag Olamine丨CAS 496775-62-3 is a critical therapeutic agent for managing thrombocytopenia in a variety of hematological disorders. Its targeted stimulation of platelet production via the thrombopoietin receptor, combined with oral administration and good bioavailability, makes it a valuable option for patients needing effective, convenient treatment to reduce bleeding risk and improve hematological health.
Previous
Next